Spring til hovednavigation Spring til søgning Spring til hovedindhold

International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: The EORTC QLQ-SURV100

  • Louis Fox*
  • , Marieke van Leeuwen
  • , Jennifer M. Jones
  • , Amal Al-Omari
  • , Haneen Abaza
  • , Muna Al-Khaifi
  • , Martin Eichler
  • , Sue Hartup
  • , Galina Velikova
  • , Nanna Friðriksdóttir
  • , Juhee Cho
  • , Nathalie Vanlaer
  • , Anne Rogiers
  • , Stefania Costi
  • , Silvia Soncini
  • , Trille Kristina Kjær
  • , Volker Arndt
  • , Daniela Doege
  • , Ali Alkan
  • , Hiroto Ishiki
  • Elke Rammant, Jannike Baumann, Marianne Sinn, Maria Antonietta Annunziata, Juan Ignacio Arraras, Mieke Van Hemelrijck, Andrea Pace, Naomi Clatworthy, Victoria King, Lærke Kjær Tolstrup, Akihiko Shimomura, Meropi Kontogianni, Samantha C. Sodergren, Nikolina Vukšić, Morten Aagaard Petersen, Jacobien M. Kieffer, Michael Jefford, Tara Chalk, Teresa Young, Nayanaben Borda, Ofir Morag, Amelie Harle, Duška Petranović, Elena Meggiolaro, Silvia De Padova, Femke Jansen, Nazim Serdar Turhal, Chiara Maria Navarra, Ingo Baumann, Cecilie Delphin Amdal, Vassilios S Vassiliou, Monica Pinto, Saiko Kurosawa, Ingvild Vistad, Muna Al-Balushi, Ahmad Al-Ghoche, Linda Dirven, Andreia Capela, Zeinab Elsayed, Sara Montemuiño, Patricia Willisch, Neil K Aaronson, Lonneke van der Poll-Franse, on behalf of the EORTC Quality of Life Group
*Corresponding author af dette arbejde

Abstract

Introduction Cancer survivors face unique and persistent health-related quality of life (HRQoL) challenges. Existing HRQoL questionnaires for survivors lack content regarding chronic physical issues and have typically included limited cancer types and languages/cultures, affecting breadth of content and generalisability. We developed and validated the EORTC QLQ-SURV100, a questionnaire to assess HRQoL in disease-free survivors of diverse cancers. A conceptual framework of HRQoL in cancer survivors, developed in previous study phases and conceptualised as survivors’ self-reported physical, mental and social functioning and well-being, formed the basis for questionnaire content. Methods The QLQ-SURV100 was administered to 1480 participants across 46 centres in 21 countries (31% breast cancer, 23% colorectal, 22% prostate, 24% other cancers), who had completed primary treatment 1–10 years earlier and had no evidence of active disease. Structural validity of the 21 multi-item questionnaire scales was assessed via confirmatory factor analysis; test-retest reliability via intraclass correlation coefficients (ICCs); construct validity through known-group comparisons; and cross-cultural validity and sex invariance through differential item functioning (DIF). Item response theory (IRT) analyses evaluated item redundancy and performance. Results The QLQ-SURV100 showed strong structural validity (Comparative Fit Index = 0.951; Tucker-Lewis Index = 0.944; Root Mean Square Error of Approximation = 0.046), with most standardised factor loadings ' 0.7. Test-retest ICCs exceeded 0.7 for 27 of 35 scales and 0.6 for 34 scales. Known-groups analyses supported most hypotheses, confirming sensitivity to treatment, comorbidity, age, sex, and education. DIF analysis indicated minor cross-cultural item bias, but no sex-related DIF. IRT analysis found no redundant items. Conclusions The EORTC QLQ-SURV100 showed satisfactory structural validity, test-retest reliability and construct validity; limited item redundancy; and measurement invariance across the sex and language groups examined.

OriginalsprogEngelsk
Artikelnummer116959
TidsskriftEuropean Journal of Cancer
Vol/bind245
ISSN0959-8049
DOI
StatusUdgivet - 9 sep. 2026

Fingeraftryk

Dyk ned i forskningsemnerne om 'International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: The EORTC QLQ-SURV100'. Sammen danner de et unikt fingeraftryk.

Citationsformater